Track VRTX in your personal workspace
Monitor performance, SPY relative strength
and WOI View from your watchlist.
Alert me when VRTX price is:
52W Range Position
65%
LOWMIDHIGH
Trend
Constructive
Momentum
Neutral
Updated: 2026-07-31 15:44 UTC
WOI Investment Thesis
Constructive
Confirmation improves above 529.59. Holding above 472.34 keeps the current thesis intact.
⚖️
✓
Fundamentals
Improving / Positive
✓
Price Structure
Constructive
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Elevated
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
472.34
↗
Break Above
Confirmation improves above resistance.
529.59
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below 472.34
Recent Company Events
SEC VERIFIED
Latest material filings
JUL
7
◆
M&A
HIGH
VRTX merger or acquisition update
Merger Agreement On July 6, 2026, Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (“ Parent ”), Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Merger Sub ”), and Crinetics Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), entered into an Agre...
Merger Agreement On July 6, 2026, Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (“ Parent ”), Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Merger Sub ”), and Crinetics Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”).
8-K Filing•SEC EDGAR
MAY
13
●
Management / Board
MEDIUM
VRTX board and management update
Departure of Directors of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officer On March 27, 2026, the Board of Directors (the "Board") of Vertex Pharmaceuticals Incorporated (the "Company") approved the Vertex Pharmaceuticals Incorporated...
Departure of Directors of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officer On March 27, 2026, the Board of Directors (the "Board") of Vertex Pharmaceuticals Incorporated (the "Company") approved the Vertex Pharmaceuticals Incorporated 2026 Stock and Option Plan (the "2026 Plan"), which replaces the Vertex Pharmaceuticals Incorporated 2013 Stock and Option Plan, subject to shareholder approval.
8-K Filing•SEC EDGAR
MAY
4
●
Financial Results
HIGH
Vertex Reports First Quarter 2026 Financial Results
— Total revenue of $2.99 billion, an 8% increase compared to first quarter 2025 — — Povetacicept program continues rapid advancement: Completed rolling BLA submission for U.S.
8-K Filing•SEC EDGAR
What's Driving VRTX?
📈 Technical recovery is improving
Momentum is Neutral. Watch 529.59 for confirmation and 472.34 for structure risk.
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
45.9
◎
How to read this setup
The next meaningful technical decision is likely to occur between support at 472.35 and resistance at 480.45. Clearing resistance would strengthen the constructive case, while a failure through support would damage the present setup.